US Patent 12103977 Trispecific antibody targeting CD79b, CD20, and CD3
Patent 12103977 was granted and assigned to Janssen Biotech on October, 2024 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 12103977 Trispecific antibody targeting CD79b, CD20, and CD3
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.